GBA (Glucosylceramidase, Beta), located on chromosome 1q21, encodes the lysosomal enzyme glucocerebrosidase (GCase), which catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Pathogenic variants in GBA are the most significant genetic risk factor for Parkinson's disease (PD), particularly in Ashkenazi Jewish populations where carrier frequency can reach 15-20%. GBA variants are also associated with Gaucher disease, a lysosomal storage disorder, creating a complex relationship between Gaucher disease carriers and PD risk.
The GBA gene encodes glucocerebrosidase (GCase), a 536-amino acid lysosomal hydrolase:
- Lipid metabolism: Catalyzes glucosylceramide hydrolysis in lysosomes
- Autophagy regulation: Critical for autophagosome-lysosome fusion
- Protein homeostasis: Involved in alpha-synuclein degradation pathways
- Mitochondrial function: Affects mitochondrial dynamics and function
- ER stress: GCase deficiency triggers unfolded protein response
- Neuroinflammation: Modulates microglial activation and cytokine production
GCase is synthesized in the ER, folded, and transported to lysosomes via the secretory pathway. The enzyme requires cofactors (saposin C, negatively charged lipids) for optimal activity.
| Feature |
Details |
| Molecular weight |
~59.7 kDa (precursor), ~56.6 kDa (mature) |
| Structure |
3-domain: TIM barrel (catalytic), beta-sandwich, allosteric domain |
| Active site |
Glu235, Glu340 |
| Post-translation |
N-glycosylation, signal peptide cleavage |
| Crystal structure |
PDB: 1OGS, 2V3D |
- Risk factor: GBA variants are the most common genetic risk factor for PD.
- Mechanism: Multiple mechanisms including:
- Impaired autophagy-lysosomal pathway function
- Enhanced alpha-synuclein aggregation
- Mitochondrial dysfunction
- ER stress induction
- Lysosomal lipid accumulation
- Altered immune response
- Phenotype: Earlier onset (mean ~58 years), more cognitive impairment
- Progression: Faster motor progression, higher risk of dementia
- Neuropathology: More widespread alpha-synuclein pathology
- Response: Similar levodopa response but more neuropsychiatric complications
- Type 1: Non-neuronopathic, most common
- Type 2/3: Acute/Chronic neuronopathic forms
- Carrier risk: Heterozygote carriers have increased PD risk (OR 2.1-5.5)
- Lewy body dementia: GBA variants increase risk similar to PD
- Multiple system atrophy: Possible association under investigation
- Progressive supranuclear palsy: Some studies suggest increased risk
- Brain: Low expression in most regions; higher in substantia nigra, putamen
- Cell types: Expressed in neurons, astrocytes, microglia
- Subcellular: Lysosomal localization
- Regulation: Transcription factor EB (TFEB) regulates GBA expression
- Aharon-Peretz et al., GBA mutations and Parkinson disease (2004)
- Sidransky et al., Multicenter analysis of GBA in PD (2009)
- Mazzulli et al., GBA deficiency promotes alpha-synuclein aggregation (2011)
- Schapira, GBA and Parkinson's disease (2015)
- Nalls et al., Large-scale meta-analysis of GBA in PD (2019)
- Balestrino et al., GBA-related Parkinsonism: clinical features (2020)
- Liu et al., GBA gene therapy approaches (2022)
- Vitale et al., GBA modifiers of alpha-synuclein pathology (2023)
- Molecular chaperones: Ambiguous, afegostat, lucerastat
- Gene therapy: AAV-GBA delivery in preclinical models
- Substrate reduction: GZ/SAR402671
- Lysosomal function restoration
- Autophagy enhancement
- Alpha-synuclein clearance
- Mitochondrial protection